Therivabio
Rockville, US · 18 employees on LinkedIn · 1 known investors
Find your way into Therivabio
160 people in our graph share verified history with the Therivabio team — schools, employers, funds. One of them is your warm intro.
Prashant Shahunlockedknows Steven A. Shallcross · together at The University of Chicago Booth School of Business (overlapped)
×3knows the team · via The University of Chicago Booth School of Business
×8knows the team · via University of Illinois Chicago
Theriva Biologics is a clinical-stage company developing therapeutics for cancer and related diseases, including an oncolytic adenovirus platform (VCN-01) and enzyme-based candidates for gastrointestinal and systemic conditions (SYN-004, SYN-020). It is a publicly traded biopharmaceutical company (NYSE American: TOVX) focused on areas of high unmet medical need.
Founders & leadership
SA
Steven A. ShallcrossinChief Executive Officer, Chief Financial Officer and DirectorShallcross joined the company in 2015 as Chief Financial Officer and Treasurer before taking on the interim chief executive role in 2017 and the permanent post in 2018. He previously served as EVP and CFO at Nuo Therapeutics and Empire Petroleum Partners, acted as CFO for Sensors for Medicine & Science, and held board seats at Elys Game Technology and Twin Vee PowerCats.
JS
Joseph SlimanExecutive
JR
Jeffrey RileyinExecutive
ST
Scott TarriffNamed on SEC filing
Board
JJ
Jeffrey J. KrawsBoard director
JA
Jeffrey A. WolfBoard director
JM
John MonahanBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$29.6M disclosed across 4 rounds · 2017–2025
▶$13.1MraisedOct 2025 · 10 investors · BiotechnologyRule 506(b)
▶$13.1MraisedOct 2025 · 10 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jeffrey J. KrawsDirector
- Jeffrey A. WolfDirector
- John MonahanDirector
- Steven A. ShallcrossExecutive Officer, Director
- Offering amount
- $13.1M
- Amount sold
- $13.1M
- Sales commissions
- $308K
- Placement agents
- A.G.P./Alliance Global Partners
- First sale
- Oct 2025
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$3MraisedAug 2022 · 1 investors · BiotechnologyRule 506(b)
▶$3MraisedAug 2022 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jeffrey WolfDirector
- Jeffrey J. KrawsDirector
- John MonahanDirector
- Steven A. ShallcrossExecutive Officer, Director
- Offering amount
- $3M
- Amount sold
- $3M
- Minimum investment
- $3M
- Finders' fees
- $175K
- Placement agents
- A.G.P./Alliance Global Partners
- First sale
- Jul 2022
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$1.5MraisedMar 2022 · 4 investors · BiotechnologyRule 506(b)
▶$1.5MraisedMar 2022 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Steven A ShallcrossExecutive Officer, Director
- Jeffrey J. KrawsDirector
- John MonahanDirector
- Jeffrey WolfDirector
- Offering amount
- $1.5M
- Amount sold
- $1.5M
- First sale
- Mar 2022
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
▶$12MraisedSep 2017 · 1 investors · BiotechnologyRule 506(b)
▶$12MraisedSep 2017 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Scott TarriffDirector
- Jeffrey KrawsDirector
- Joseph SlimanExecutive Officer
- Jeffrey WolfDirector
- Steven ShallcrossExecutive Officer
- Jeffrey RileyExecutive Officer, Director
- Offering amount
- $12M
- Amount sold
- $12M
- Minimum investment
- $12M
- First sale
- Sep 2017
- Incorporated
- Corporation, Nevada
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 1
by search overlapCompanies competing with Therivabio for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Therivabio do?
- Theriva Biologics is a clinical-stage company developing therapeutics for cancer and related diseases, including an oncolytic adenovirus platform (VCN-01) and enzyme-based candidates for gastrointestinal and systemic conditions (SYN-004, SYN-020). It is a publicly traded biopharmaceutical company (NYSE American: TOVX) focused on areas of high unmet medical need.
- Who are Therivabio's investors?
- Therivabio's investors include Kinled Holding.
- How much funding has Therivabio raised?
- Therivabio has disclosed $29.6M raised across 4 rounds.
- Where is Therivabio headquartered?
- Therivabio is headquartered in Rockville, US.